Overview

A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

Status:
Recruiting
Trial end date:
2021-09-03
Target enrollment:
Participant gender:
Summary
This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Eidos Therapeutics
Eidos Therapeutics, a BridgeBio company